Defects in apoptotic cell death can promote cancer and impair responses of malignant cells
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by keeping the cell …

The discovery of the BRAFV600E mutation led to the development of vemurafenib
(PLX4032), a selective BRAF inhibitor specific to the kinase, for the treatment of metastatic …

Malignant melanoma is one of the most difficult cancers to treat due to its resistance to
chemotherapy. Despite recent successes with BRAF inhibitors and immune checkpoint …

BH3 mimetics, targeting the Bcl-2 family anti-apoptotic proteins, represent a promising
therapeutic opportunity in cancers. ABT-199, the first specific Bcl-2 inhibitor, was approved …

Resisting cell death is a hallmark of cancer. Disturbances in the execution of cell death
programs promote carcinogenesis and survival of cancer cells under unfavorable …

Anaplastic thyroid carcinomas (ATCs) have a high prevalence of BRAF and TP53 mutations.
A trial of vemurafenib in nonmelanoma BRAFV600E-mutant cancers showed significant …

Melanoma of the skin has become a prime example for demonstrating the success of
targeted cancer therapy. Nevertheless, high mortality has remained, mainly related to tumor …

Highlights•The Bcl‐2 family proteins are mainly involved in the control of intrinsic apoptotic
pathway•The pro-survival members of Bcl‐2 family are over-expressed in melanoma.•Bcl‐2 …

The deregulation of apoptosis is a key contributor to tumourigenesis as it can lead to the
unwanted survival of rogue cells. Drugs known as the BH3-mimetics targeting the pro …

Abstract Metastatic BRAF V600E colorectal cancer (CRC) carries an extremely poor
prognosis and is in urgent need of effective new treatments. While the BRAFV600E inhibitor …